A decade ago, the drug-target residence time model has been (re-)introduced, which describes the importance of binding kinetics of ligands on their protein targets. Since then, it has been applied successfully for multiple protein targets, including GPCRs, for the development of lead compounds with slow dissociation kinetics (i.e. long target residence time) to increase in vivo efficacy or with short residence time to prevent on-target associated side effects. To date, this model has not been applied in the design and pharmacological evaluation of novel selective ligands for the cannabinoid CB 2 receptor (CB 2 R), a GPCR with therapeutic potential in the treatment of tissue injury and inflammatory diseases. Here, we have investigated the relationships between physicochemical properties, binding kinetics and functional activity in two different signal transduction pathways, G protein activation and β-arrestin recruitment. We synthesized 24 analogues of 3-cyclopropyl-1-(4-(6-((1,1-dioxidothiomorpholino)methyl)-5-fluoropyridin-2-yl)benzyl)imidazoleidine-2,4-dione (LEI101), our previously reported in vivo active and CB 2 R-selective agonist, with varying basicity and lipophilicity. We identified a positive correlation between target residence time and functional potency due to an increase in lipophilicity on the alkyl substituents, which was not the case for the amine substituents. Basicity of the agonists did not show a relationship with affinity, residence time or functional activity. Our findings provide important insights about the effects of physicochemical properties of the specific substituents of this scaffold on the binding kinetics of agonists and their CB 2 R pharmacology. This work therefore shows how CB 2 R agonists can be designed to have optimal kinetic profiles, which could aid the lead optimization process in drug discovery for the study or treatment of inflammatory diseases.
Introduction
Traditionally, in drug discovery, the affinity or potency of a drug candidate for a given target was considered a key determinant for in vivo activity, but later it was found that these parameters do not correlate as well as originally thought [1, 2] . In contrast, the binding kinetics of a ligand for a given target, in particular slow dissociation kinetics and therefore a long target residence time, may be a better predictor of in vivo efficacy in specific cases [3] [4] [5] [6] , as emphasized by several excellent reviews [7] [8] [9] . For example, a correlation was found between long residence time of Fab-l enoyl reductase inhibitors and their in vivo activity in a mouse model of tularemia infection, leading to prolonged survival of the mice [3, 4] . Recently, this "drug-target residence time model" has aided several clinical-stage drug development programs [10, 11] by selecting compounds with high efficacy [12] , or reduced on-target toxicities [13] . However, the association rate is increasingly recognized as well as an important factor in determining a ligand's functional activity. For example, slowly associating ligands may decrease on-target related side effects by preventing high target occupancy and fast target activation [14] , while fast associating ligands may have an influence in prolonged activity if rebinding occurs [15] .
Retrospective analysis of marketed drugs for G protein-coupled receptors (GPCRs), an important class of drug targets, revealed that the beneficial effects of some of these drugs may be attributed to their long drug-target residence times [8] . Interestingly, in case of GPCR agonists, a positive correlation was also found between long residence time and in vitro efficacy for the Adenosine A 2A receptor [16] and the Muscarinic M 3 receptor [17] . For the latter, it was also shown that long target residence time of an antagonist, i.e. tiotropium, resulted in so-called kinetic selectivity over the other muscarinic receptor subtypes, thereby tive substituent in cannabis [21] . In contrast, the CB 2 R is predominantly abundant in immune cells, is involved in cell migration and immunosuppression [22, 23] , and is upregulated during pathophysiological conditions [24] . CB 2 R activity has been associated with therapeutic benefits in inflammatory or immune system related pathologies [24, 25] . Selective activation of the CB 2 R is therefore associated with therapeutic benefits and may prevent CB 1 R-mediated adverse side effects.
Recently, our group reported on 3-cyclopropyl-1-(4-(6-((1,1-dioxidothiomorpholino)methyl)-5-fluoropyridin-2-yl)benzyl)imidazoleidine-2,4-dione (LEI101) (Fig. 1) , a promising CB 2 R partial agonist [26] . LEI101 showed in vivo efficacy in preclinical models of neuropathic pain and cis-platin-induced nephrotoxicity [26, 27] . The CB 2 R kinetic profile of LEI101 is unknown, therefore we were interested to systematically investigate the binding kinetics and functional activity of this chemical series.
To this end, we synthesized a library of 24 compounds based on the scaffold of LEI101 (Fig. 1) , in which we systematically varied their basicity and lipophilicity (pK a and LogP) of the R 1 (amine) and R 2 (alkyl) substituents and determined their equilibrium binding affinity and Kinetic Rate Index (KRI), a high-throughput measure as an indication for ligand-receptor kinetics [28] . In addition, the full kinetic profile, as well as functional potency and efficacy in G protein activation and β-arrestin recruitment, was measured for 14 of these compounds. Correlation analysis of the data identified a relationship between target residence time and potency in both signal transduction pathways due to increased lipophilicity specifically on the R 2 position.
This work provides important insights in the impact of divergent binding kinetics of LEI101-based agonists on CB 2 R pharmacology and the role of physicochemical properties therein. In turn, these insights show how CB 2 R agonists can be designed to have optimal kinetic profiles, which will aid the lead optimization process in drug discovery for the study or treatment of inflammatory diseases.
Materials and methods

Chemical and reagents
All common reagents were purchased from commercial sources and used as received. The agonist library was synthesized as described previously in van der Stelt et al., 2011 [27] , with only small modifications (see Fig. 2 ). After purification, all compounds had more than 95% purity as determined by Liquid Chromatography Mass Spectroscopy (LCMS), by measuring UV absorbance at 254 nm and were fully characterized using 1 and GF-B/GF-C filters were purchased from Perkin Elmer (Waltham, MA). Bicinchoninic acid (BCA) and BCA protein assay reagent were obtained from Pierce Chemical Company (Rochford, IL). The PathHunter® CHO-K1 CNR1 (CHOK1hCB 1 _bgal) and CNR2 (CHOK1hCB 2 _bgal) β-Arrestin Cell Lines and the PathHunter® detection kit were obtained from DiscoveRx (Fremont, United States). Cell culture plates were purchased from Sarstedt and 384-well white walled assay plates from Perkin Elmer. All buffers and solutions were prepared using Millipore water (deionized using a MilliQ A10 Biocel™, with a 0.22 µm filter) and analytical grade reagents and solvents. Buffers are prepared at room temperature and stored at 4°C, unless stated otherwise.
Cell culture
CHOK1hCB 2 _bgal cells were cultured in Ham's F12 Nutrient Mixture, supplemented with 10% fetal calf serum, 1 mM glutamine, 50 U/mL penicillin, 50 μg/mL streptomycin, 300 mg/mL hygromycin and 800 μg/mL geneticin in a humidified atmosphere at 37°C and 5% CO 2, as reported previously [29] . Cells were subcultured twice a week at a ratio of 1:20 on 10-cm diameter plates by trypsinization. For membrane preparation the cells were subcultured 1:10 and transferred to 15-cm diameter plates. Cells were passaged no longer than 25 times or 3 months.
Membrane preparation
Per batch of membranes, cells on thirty 15-cm ø plates were detached from the bottom by scraping them into 5 mL phosphate-buffered saline (PBS), collected in 12 mL Falcon tubes and centrifuged for 5 min at 200g (3000 rpm). The pellets were resuspended in ice-cold 50 mM Tris-HCl buffer and 5 mM MgCl 2 (pH 7.4). An Ultra Thurrax homogenizer (Heidolph Instruments, Schwabach, Germany) was used to homogenize the cell suspension. The membranes and cytosolic fractions were separated by centrifugation at 100,000g (31,000 rpm) in a Beckman Optima LE-80 K ultracentrifuge (Beckman Coulter Inc., Fullerton, CA) at 4°C for 20 min. The pellet was resuspended in 10 mL of Tris-HCl buffer and 5 mM MgCl 2 (pH 7.4) and the homogenization and centrifugation steps were repeated. Finally, the membrane pellet was resuspended in 10 mL 50 mM Tris-HCl buffer and 5 mM MgCl 2 (pH 7.4) and aliquots of 250 μL were stored at −80°C. Membrane protein concentrations were measured using the BCA method [30] . 50 values, and nonspecific binding was determined in the presence of 10 μM AM630. Incubations were terminated and samples harvested as described by the 96-wells harvest procedure (see below).
96-wells harvest procedure
Samples were harvested on 96-wells GF/C filters, precoated with 25 μL 0.25% (v/v) PEI per well, with rapid vacuum filtration, to separate the bound and free radioligand, using a Perkin Elmer 96-wells harvester (Perkin Elmer, Groningen, The Netherlands). Filters were subsequently washed ten times with ice-cold assay buffer on the 96-well plate and 5 times on a wash plate. Filter plates were dried at 55°C for ∼45 min, then 25 μL Microscint was added per well (Perkin Elmer, Groningen, The Netherlands). After 3 h, the filter-bound radioactivity was determined by scintillation spectrometry using a Microbeta2® 2450 microplate counter (Perkin Elmer, Boston, MA). For fast determination of the relative kinetics of the agonist library, the KRI was determined using a dual-point competition association assay based on previously published methods [28] . The agonists were incubated at their IC 50 concentration (as determined at 25°C) with 1. introduced with a peptide coupling using cyclopropylamine, followed by cyclization to intermediate 36g. 33a was first cyclized to the hydantoin and then functionalized with the R 2 substituent with an alkylation reaction, resulting in R 2 -substituted intermediates 36a-f, which were converted in two steps to final compounds using subsequently a Miyaura borylation and Suzuki coupling reaction with intermediates 28a-g [27] . Reagents and conditions: a) NaBH 4 a total volume of 100 μL, for either 1 or 2 h at 10°C (t 1 and t 2 , respectively). Nonspecific binding was determined by addition of 10 μM AM630 from the start of the assay. Incubations were terminated and samples harvested as described by the 96-wells harvest procedure (see above).
[ 3 H]CP55940 full competition association assay
To determine the k on and k off values of unlabeled competing ligands. Ligands were incubated at their IC 50 concentration (see 2.12 Data Analysis) in presence of ∼1.5 nM [ 
[ 35 S]GTPγS assay
G protein activation as a measure for receptor activity was determined by the binding of radiolabeled non-hydrolyzable GTP ( [S 35 ]GTPγS) to the receptor [29, 31] . To homogenized CHOK1CB 2 R_bgal membranes (5 µg) in 20 µL assay buffer (50 mM TrisHCl buffer (pH 7.4), 5 mM MgCl 2 , 150 mM NaCl, 1 mM EDTA, 0.05% BSA and 1 mM DTT, freshly prepared every day), 5 µg saponin and 1 µM GDP were added (final assay concentration). To determine the pEC 50 and E max values of the agonist library, the membranes were directly 
PathHunter® β-Arrestin recruitment assay
The assay was performed using the PathHunter® CHOK1CB 2 R_bgal cells and β-arrestin recruitment assay kit (DiscoveRx Corporation, Fremont, CA), as published before [29, 32] . Briefly, PathHunter® CHOK1hCB 2 R_bgal cells were seeded at a density of 5000 cells per well of solid white walled 384-well plates (Perkin Elmer, MA, USA) in 20 μL HAM's F12 Nutrient Mixture culture medium and incubated overnight in a humidified atmosphere at 37°C and 5% CO 2 . The cells were stimulated with 5 μL of 50 μM (10 μM final assay concentration) of each agonist (single point assay) or 10 increasing concentrations of each agonist and incubated for 90 min in a humidified atmosphere at 37°C and 5% CO 2 . The DMSO concentration was the same in each well. The activity of β-galactosidase was determined using the PathHunter® Detection Kit (DiscoveRx Corporation, Fremont, CA), following the supplier's protocol. In short, the cells were loaded with 12 μL detection reagent (DiscoveRx Corporation, Fremont, CA) and incubated for 1 h in the dark at room temperature. Luminescence (400-700 nm), indicated as relative light units (RLU), was measured on an EnVision multilabel plate reader (Perkin Elmer, MA, USA), using a Luminescence 700 emission filter.
Data analysis
cLogP and pK a values were calculated using ChemDraw® Professional 16.0 (Perkin Elmer). All experimental data were analyzed using the nonlinear regression curve fitting program GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA). From displacement assays at 25°C, the non-linear regression analysis for one site -Fit Ki was used to obtain logK i values, which are provided by Prism by direct application of the Cheng-Prusoff equation [33] : ) and k off (2.0 ± 0.1 × 10 [ 3 H]CP55940 at this temperature were determined using an association and dissociation assay, respectively (three experiments performed in duplicate, data not shown). The logK i values were converted manually to pK i values (Table 1) . For the kinetic experiments, a concentration equal to the IC 50 value of each agonist was used, as determined from the non-linear regression analysis for "one site -Fit logIC 50 ". For non-linear regression analysis "one site -Fit K i " and "one site -Fit logIC 50 " the top and bottom of the curve were constrained at 100 and 0, respectively. From association assays, the association rate constant (k on ) of ]CP55940 was determined using Prism's "one-phase exponential decay" analysis using the following formula: Y = (Y0 − NSB) * exp(−k off * t) + NSB, where k off is the dissociation rate constant in min −1 and where Y0 is the specific radioligand binding at time 0 (constrained at 100). From competition association assays, the k on and the k off of cold ligands were obtained by non-linear regression analysis "kinetics of competitive binding" that uses the following equation [34] :
, using the following variables: ) and k off (s
−1
). Receptor residence time (RT, in min) was calculated by taking the reciprocal of the dissociation rate as follows room temperature = 1/(60 * k off ), as k off is in s −1 . β-Arrestin recruitment and GTPγS data were analyzed by Prism's nonlinear regression analysis "log (agonist) vs. response -variable slope" to obtain potency (EC 50 ) and efficacy (E max ) values of ligands. The efficacy of all agonists was normalized to the effects of 10 μM CP55940. The bottom of the curves were constrained at 0. All data was obtained from three separate experiments performed in duplicate, unless stated otherwise. The correlation between two independent variables or data sets was calculated using a two-tailed Pearson correlation analysis [35] . A Pvalue of less than 0.05 was considered significant.
Results
Equilibrium binding affinity of the LEI101-library
The affinities of the 24 newly synthesized compounds were determined in a radioligand displacement assay using [ 3 H]CP55940 as the radiolabeled competitor at a temperature of 25°C. The structure, affinity (pK i ) and physicochemical properties of the library are presented in 
High throughput kinetic screening of LEI101-library
Next, the binding kinetics of all compounds were determined using the high throughput dual-point competition association assay, yielding Kinetic Rate Index (KRI) values that describe the relative (dissociation) kinetics of the agonist library compared to the radioligand used, [ 3 H]CP55940. These experiments, and all the following kinetic experiments, were performed at a reduced temperature of 10°C to increase the 'resolution' of the assay, enabling us to examine the influence of different physicochemical properties on the relative binding kinetics of the compounds within the library. Firstly, we validated that the affinities of the molecules were similar (particularly in rank order) at 10°C as compared to 25°C using a selection of 8 representative agonists with low, moderate and high affinity (data not shown). Subsequently, we used a single concentration of the compounds (1.0 × IC 50 ) for determination of the KRI values (Table 1) . Most compounds had a KRI value lower than 1.0, which indicates a residence time (RT) shorter than that of [ 3 H]CP55940. Compounds 2, 4 and 6 had the lowest KRI values (0.53 ± 0.06, 0.52 ± 0.09 and 0.51 ± 0.05, respectively), whereas only 7, 22 and 23 had a KRI value larger than 1.0 (1.06 ± 0.11, 1.21 ± 0.07 and 1.03 ± 0.08, respectively). These three compounds all have an isobutyl moiety at the R 2 position, the most lipophilic substituent in this series, but have different R 1 substituents, a dioxidethiomorpholine (7), a piperidine (22), or a methylpiperidine (23).
Full kinetic profiling of the LEI101-library
Based on the results from the KRI screen, twelve agonists were selected for further kinetic characterization. These compounds contained a dioxidethiomorpholine at the R 1 position (group A, compounds 1-7)
or an isobutyl group at the R 2 position (group B, compounds 7, 8, 15,
17, 22, 23).
Of note, compound 7 belongs to both groups. The molecules comprised a wide range of KRI values between 0.51 and 1.21, respectively the lowest and highest KRI measured in this agonist library. Together this allowed a comprehensive investigation of structure-kinetic relationships at the CB 2 R. We used a competition association assay with [ 3 H]CP55940 that yielded the association-and dissociation rate constants (k on and k off values, respectively) of the compounds (Table 2) . A significant correlation between the KRI values and k off values was found (Fig. 3A) . The association of [ 50 ± SEM and E max ± SEM were obtained from a PathHunter® β-arrestin recruitment assay at 37°C, on live CHOK1CB 2 R cells (N = 3 in duplicate). Moreover, the variety in k on and k off values was visualized using a kinetic map (Fig. 3C) , while compounds with a dissociation rate between 10 −3 and 10 −2 s −1 (dashed circle) predominantly had a K D between 10 −7 and 10 −8 M, due to a small variety in their k on values. Of note, 1 (R 2 = H) had a 10-fold smaller k on value compared to the other compounds, thereby making it an outlier in the kinetic map (Fig. 3C) . The kinetic K D values of all compounds (Table 2 ) were compared to the equilibrium affinities (K i values) (Fig. 4A) . A statistically significant correlation was found between the negative logarithm of the kinetic K D (10°C) and the equilibrium pK i (25°C). Of note, the pK D values were all 0.5 log unit (∼3-fold) higher than the pK i values. A correlation between pK D and k off or residence time was also identified (Fig. 4B,C) , but not between pK D and k on values (Fig. 4D) .
Structure-kinetics relationships
The kinetic profile of the compounds was used to derive structurekinetics relationships. The longest residence times (RT > 30 min) were displayed by compounds with a propyl (6, RT = 32 ± 9 min) or isobutyl group at the R 2 position (7, 8, 17, 22 and 23, RT = 71 ± 3, 37 ± 5, 72 ± 8, 69 ± 2 and 31 ± 6 min, respectively). Compounds 2 and 3 displayed the shortest residence times (RT = 2.2 ± 0.8 and 3.6 ± 1.5 min, respectively). Interestingly, the residence time of 1 was similar as LEI101 (4) (RT = 14 ± 6 and 8.8 ± 1.6 min for 1 and 4, respectively), despite a 10-fold lower binding affinity (pK i = 5.55 ± 0.08 and 6.51 ± 0.09 for 1 and 4, respectively), which was due to the very low k on value of 1 (2.2 ± 1.0 × 10 3 M −1 s
−1
).
Influence of physicochemical properties on affinity and binding kinetics
Next, we analyzed the effects of physicochemical properties on equilibrium affinity and binding kinetics. Hence, the cLogP (Table 1) Fig. 5C ). Noteworthy, this correlation was not observed with the R 1 substituents of group B (Fig. 6 ).
Influence of binding kinetics on functional activity
Finally, the influence of residence time on functional activity of the compound library was investigated. To this end, both groups were characterized in two functional assays: GTPγS binding and β-arrestin recruitment ( Table 2 ). All compounds displayed partial agonism in both assays relative to CP55940. The highest intrinsic efficacy was observed for 5 in the G protein activation assay (E max = 79 ± 14%), whereas agonist 2 had the highest efficacy in the β-arrestin recruitment assay (E max = 76 ± 15%). The lowest efficacy was observed for 1 in both functional assays (β-arrestin: E max = 25 ± 2%; GTPγS: E max = 48 ± 7%). Generally, agonists showed a lower efficacy for β-arrestin recruitment, except for agonists 2, 6 and 15 (E max β-arrestin: 76 ± 15, 62 ± 8 and 64 ± 10 compared to E max GTPγS: 54 ± 13, 50 ± 2 and 65 ± 12, respectively), although these differences were not significant. Indeed, no correlation was observed between the efficacies of the compounds in the two functional assays (Pearson r: 0.4247, p-value = 0.1688, correlation graphs not shown). In addition, no correlation between residence time and in vitro efficacy was identified (GTPγS Pearson r: 0.00621, p-value: 0.9895; β-arrestin Pearson r: 0.1053, p-value 0.8222, graphs not shown). For example, the long residence time of agonists 6, 7, 8, 17, 22 and 23 did not have a higher efficacy than the other agonists in either functional assay. In fact, agonist 2 with the shortest residence time (2.2 ± 0.8 min) had a very moderate efficacy in GTPγS (54 ± 13%), and the highest efficacy of all agonists for β-arrestin recruitment (76 ± 15%).
The potencies ranged from 6.06 ± 0.27 (3) to 7.94 ± 0.24 (7) in the GTPγS assay, whereas in the β-arrestin recruitment assay the potencies ranged from 6.12 ± 0.23 (1) to 8.14 ± 0.08 (22) . In contrast to efficacy, the potency of the compounds was similar and highly correlated in the two functional assays (Pearson r: 0.8445, p-value < 0.0005). In general the compounds showed a higher potency in β-arrestin recruitment assays. For example, 22 showed a 17-fold higher potency for β-arrestin recruitment compared to G protein activation (pEC 50 = 8.14 ± 0.08 and 6.91 ± 0.32, respectively).
Notably, nanomolar potency (pEC 50 > 7.5) was only displayed by agonists with a residence time of at least 30 min as exemplified by compounds 6, 8 and 23 (with residence times of 32 ± 9, 37 ± 5 and 31 ± 6 min, respectively) and compounds 7, 17 and 22 (RT = 71 ± 3, 72 ± 8 and 69 ± 2 min, respectively). A statistically significant correlation was found of the residence times of group A with functional potency for both G protein activation and β-arrestin recruitment (Fig. 7A,B) . Interestingly, the residence times of group B did not correlate with either potency or efficacy (GTPγS E max Pearson r: 0.0021, p-value: 0.9968; pEC 50 Pearson r: 0.3391, p-value: 0.5108; β-arrestin E max Pearson r: −0.2591, p-value: 0.6200; pEC 50 Pearson r: 0.6586, p-value: 0.1549, graphs not shown).
Discussion
Kinetic characterization of LEI101-based agonists
Recently, drug discovery research has focused on the development of selective CB 2 R agonists for the treatment of tissue injury and inflammatory diseases that avoid inducing CB 1 R-mediated psychoactive side effects. CB 2 R knockout mice show enhanced pathology in various inflammatory disease models, including heart, liver or kidney injury and inflammatory pain, thereby supporting the notion that CB 2 R plays an essential role in these conditions. Despite compelling proof-of-concept data obtained in preclinical pain models, several CB 2 R agonists lacked efficacy in phase 2 clinical trials for unknown reasons [29, 36] .
Drug-target binding kinetics and their influence on functional activity are increasingly considered in drug discovery because it may aid in the design of lead compounds [2] . Therefore, we have investigated the relationships between functional activity and binding kinetics of a series of agonists, based on the CB 2 R-selective agonist LEI101, which showed in vivo efficacy in the treatment of neuropathic pain and inflammation-induced tissue damage [26, 27] .
In this study, radioligand binding assays were performed with [ 3 H]CP55940, an agonistic radioligand commonly used to determine CBR pharmacology [37] , including binding kinetics [38, 39] . Recently, Sykes et al. showed the importance of using physiological concentrations of sodium when determining binding kinetics at the muscarinic M3 receptor [40] . However, in this study sodium ions were absent in all assays where the agonist [ 3 H]CP55940 was used to prevent that the receptor population was forced into a predominantly inactive state, i.e. for which an agonist would have a low affinity [41] . In addition, in our system we have never observed a biphasic interaction for agonists, which would prohibit the use of the Motulsky-Mahan mathematical model as it describes binding of a ligand to a single site, e.g. receptor [34, 42] . Hence, we also did not apply GTP to force the receptor population in a single (inactive) state. Importantly, we believe that it is unlikely that the omission of sodium salts and/or GTP would result in a different rank order of binding kinetics of the agonist library. This line of thought is further corroborated by the study on tiotropium and NVA237 in presence of sodium ions that resulted in shorter residence times, but the same rank order [40] . The measured equilibrium binding affinities corresponded to previously determined structure-activity relationships (SAR) for this scaffold [27] . Using a high-throughput kinetic screening assay, based on its equivalent for the Adenosine A 1 receptor [28] , agonists with R 1 = dioxidethiomorpholine (group A) and R 2 = isobutyl (group B)
were selected for full kinetic characterization (Fig. 3A) . We found that the kinetic profile of the agonists had smaller variations in k on values, but larger variations in k off values, which were visualized using a kinetic map of the agonist library (Fig. 3C ). For this series of compounds, binding affinity was mostly influenced by their dissociation rate, as illustrated by a significant correlation with k off values, but not with k on values. (Fig. 4C,D) . This observation was similar as reported for the adenosine A 2A receptor [16, 17] , but in contrast to reports on β 2 adrenergic receptors and the hERG channel, for which the association rate was found to be the main driving force in ligand affinity [43, 44] .
The role of physicochemical properties on binding kinetics and functional activity
Previously, it has been shown that controlling physicochemical properties such as lipophilicity and basicity can lead to 'tuned drugtarget binding kinetics [8, 45, 46] . Therefore we divided our library into two groups in which we systematically varied either the lipophilicity or the basicity at different locations of the scaffold. This way, we could investigate the relationships between physicochemical properties, binding kinetics and functional activity of these agonists, for which two independent signaling pathways were used; G protein activation and β-arrestin recruitment.
A significant correlation was found between increasing lipophilicity at the R 2 position of the LEI101 scaffold and residence time (group A agonists, Fig. 5C ), but not for the R 1 position (group B agonists, Fig. 6 ).
By dividing our compound library in two parts, we showed that there is a lipophilic binding domain in the receptor targeted by the R 2 substituents. Occupying this pocket increases binding affinity due to decreased dissociation rate. Hence, it is not the overall lipophilicity of a molecule that determines its dissociation rate, but rather the lipophilicity at a specific position of the scaffold [45] . These findings fit well with the observation that any relationships between physicochemical properties and binding kinetics are both ligand and target specific and constitute the molecular underpinning of the lipophilic efficiency index [47] . Currently, there is no CB 2 R crystal structure available to validate the positioning of this lipophilic binding domain, but a lipophilic binding domain was identified in the active site of CB 1 R, formed by six amino acid residues [48, 49] This indicates that these residues may also play a role in the formation of a lipophilic binding domain responsible for the increased residence time of LEI101-based agonists with lipophilic R 2 substituents.
All compounds were identified as partial agonists in two signaling pathways, G protein activation and β-arrestin recruitment relative to CP55940 that behaved as a full agonist [51] . From these so-called 'endpoint' assays no obvious biased agonism was observed, although these molecules have different binding kinetics. However, follow up studies with regard to the influence of assay time and readout should be performed to investigate the role of kinetic context on biased agonism [52] . On a similar note, these functional assays were performed at different temperatures (i.e. 25°C and 37°C), which may influence the potency and efficacy values of the compounds tested. Although this will probably not result in a difference in rank order, it may influence the observed lack of biased signaling [52] .
Interestingly, nanomolar potency for G protein activation and β-arrestin recruitment was associated with compounds having a residence time longer than 30 min, as a significant correlation between dissociation rate and functional potency for both assays was identified (Fig. 7) . Again, this observation was specific for group A agonists. No correlation between residence time and functional efficacy was identified, as was reported for the Adenosine A 1 receptor [53] . This observation is in contrast with the previously reported positive correlation found between residence time and efficacy, but not potency, for the Adenosine A 2A receptor and Muscarinic M3 receptor [16] . Of note, for the Adenosine A 2A receptor these molecules showed significant longer residence times than the LEI101-based agonist library.
Target-specific binding kinetics in drug discovery
Previously, the CB 2 R binding kinetics of CP55940, as well as some other synthetic cannabinoid ligands (e.g. JWH133, HU308) and endocannabinoids were reported [42] . Because CP55940 was measured in both studies, we could use its binding kinetics as reference to compare the binding kinetics of the ligands tested in the two different studies. Interestingly, the kinetic profile of this agonist library shows remarkable differences compared to the reported binding kinetics of some structurally different synthetic ligands for CB 2 R, like JWH133 and SR144528 and endocannabinoids anandamide (AEA) and noladin ether (NE), which all had divergent, but relatively fast kinetics [54] . For these molecules, the association rate was the main driving force for their affinity. Knowledge of the kinetic binding parameters of a target's endogenous ligands is important for two reasons: 1) it is an indication of the ligand binding kinetics necessary to maintain homeostasis and 2) these play a major role in defining the pharmacological effect of a drug, as they have to compete with the endogenous ligands for binding to the active site [55, 56] . Notably, LEI101, identified to be in vivo active in the treatment of neuropathic pain and inflammation-induced tissue damage [26, 27] , has similar binding kinetics as 2-AG, relative to CP55940 (10-fold slower k on , 10-fold faster k off ) [54] . This may indicate that slow association plays a role in the in vivo efficacy of LEI101. Interestingly, HU308 and JWH133, also in vivo active CB 2 R-selective agonists [29, 57, 58] , had slower association rates [54] , but a similar dissociation rate, relative to CP55940 (20-50-fold slower k on , similar k off ). This may indicate that the optimal kinetic profile of in vivo active CB 2 R agonists is flexible, or may be dependent on disease type and/or progression. Although, it is noted that species differences between mouse and human CB 2 R have not been taken into account.
Interestingly, slowly associating ligands may decrease on-target related side effects by preventing high target occupancy and fast target activation [14] . This could be important, because prolonged activation of CB 2 R is hypothesized to interfere with the ECS homeostasis [54, 59] . Specifically, local, transient activation of CB 2 R by endocannabinoids may lead to immunosuppression in the early phases of the immune response, perhaps via apoptotic mechanisms [60, 61] . Rapid restoration of cellular activity might also be required to counteract potential infectious threats [62] . This indicates that the optimal kinetic profile of novel molecules needs to be established according to their functional activity, and should always be a combination of association and dissociation rates, resulting in an optimal level of receptor occupancy in vivo [63] .
Conclusion
In summary, we have reported the structure kinetics relationship of LEI101-based agonists of the cannabinoid CB 2 receptor. We identified the lipophilicity of R 2 position as important feature to increase receptor residence time, which correlated with increased potency, but not with efficacy, in two signaling pathways: G protein activation and β-arrestin recruitment. The findings of this study provide important insights into how CB 2 R agonists can be designed with desired kinetic profiles for the future development of novel treatments of inflammatory diseases.
